Gemtuzumab Ozogamicin: Back Again.
Chris Selby1, Lisa R Yacko2, Ashley E Glode3
1Division of Adult Medicine, Texas Tech University Health Sciences Center, Dallas, Texas.
Journal of the Advanced Practitioner in Oncology
|July 17, 2019
Summary
For decades, acute myeloid leukemia (AML) treatment relied on the 7+3 regimen. Gemtuzumab ozogamicin is now a new option, approved in 2017 for AML patients, offering a vital addition to therapy.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Acute myeloid leukemia (AML) treatment has seen limited pharmaceutical development for decades.
- The standard first-line therapy, the 7+3 regimen (cytarabine and daunorubicin), has been in use since 1973.
- Recent advancements include the reintroduction and approval of gemtuzumab ozogamicin.
Purpose of the Study:
- To highlight the historical context of AML treatment.
- To introduce gemtuzumab ozogamicin as a new therapeutic option for AML.
- To discuss the integration of gemtuzumab ozogamicin into clinical practice guidelines.
Main Methods:
- Review of historical treatment regimens for AML.
- Analysis of the reintroduction and approval of gemtuzumab ozogamicin.
- Examination of its inclusion in the National Comprehensive Cancer Network (NCCN) guidelines.
Main Results:
- The 7+3 regimen has been the standard of care for AML for over 45 years.
- Gemtuzumab ozogamicin was approved in 2017 and added to NCCN guidelines.
- It is indicated for both newly diagnosed and relapsed AML patients, as monotherapy or in combination with 7+3.
Conclusions:
- Gemtuzumab ozogamicin represents a significant addition to the limited treatment options for AML.
- Its inclusion in guidelines signifies a step forward in managing this aggressive leukemia.
- Ongoing exploration of gemtuzumab ozogamicin in various leukemia settings is warranted.
